Evidence map›Paper›PMID 41565702›Full record

ArticleScientific reports2026

Training and external validation of machine learning supervised prognostic models of upper tract urothelial cancer (UTUC) after nephroureterectomy.

Rossella Nicoletti, Nick Ho, Hsiang-Ying Lee, Wen-Jeng Wu, Ekaterina Laukhtina, Pietro Spatafora, Chris Ho-Ming Wong, Ivan Ching-Ho Ko, Chi-Ho Leung, Gianluca Giannarini and 13 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Rossella NicolettiS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Nick HoThe Hong Kong Polytechnic University, Hung Hom, Hong Kong.
Hsiang-Ying LeeKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Wen-Jeng WuKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Ekaterina LaukhtinaDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Pietro SpataforaDepartment of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.
Chris Ho-Ming WongS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Ivan Ching-Ho KoS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Chi-Ho LeungS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Gianluca GiannariniUnit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy.
Nikhil VasdevDepartment of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, UK.
Paolo GonteroAOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
Chi-Fai NgS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Ching-Chia LiKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Wei-Ming LiKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hung-Lung KeKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hsin-Chih YehKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Riccardo CampiDepartment of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.
Sergio SerniDepartment of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.
Mauro GacciDepartment of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.
Shahrokh ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Thomas ChoiThe Hong Kong Polytechnic University, Hung Hom, Hong Kong.
Jeremy Yuen-Chun TeohS.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. jeremyteoh@surgery.cuhk.edu.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European association of Urology (EAU) suggests a prognostic stratification of Upper Tract Urothelial Cancer (UTUC) based on high and low risk patients, with Radical nephroureterectomy (RNU) and bladder cuff resection being the gold standard for the treatment of non-metastatic High risk UTUC. However, no consensus on post-operative patient management or tools that predict who would benefit the most from a close follow-up rather than adjuvant chemotherapy regimen exist. in Machine Learning (ML) is gaining interest in Urology providing models for prognostic prediction purpose; It’s role in UTUC has not yet been investigated. We aim to develop and validate multiple supervised ML models based on patient- and tumor- related features to predict prognosis in patients with preoperative Histological or Imaging proved UTUC treated with RNU within a multiethnic large cohort. Data from an international multicenter large cohort of histologically proven UTUC patients from Asia and Europe treated with RNU were retrospectively collected. Twenty different ML-supervised predictive models were first trained and then external validate with two separate set. Nomograms were constructed based on 8 independent prognostic factors (age, gender, grading, pT, pN, presence of Carcinoma in Situ (CIS), multifocality and Lymphovascular invasion(LVI)) to predict 6 Outcomes (Overall Survival (OS), Cancer Specific Survival (CSS) and Disease Free Survival (DFS) at 3 and 5 year). Performances were compared using Area-under-curve (AUC) of Receiver-Operating Characteristics (ROC). A total of 3129 patients were enrolled: 637 Asian Patients (training cohort) and 2492 European patients (validation cohort). Upon training assessment, LR models achieved the best results, being the best model for prediction of 4/6 outcomes, with the best result in CSS both at 3 and 5 years (AUC: 0.85, 0.84, 0.81 for CSS-3y, CSS-5y and DFS-3y respectively). Upon external validation, LR(CSL) models achieve the best results, being the number 1 model for prediction of 3/6 outcomes (AUC: 0.84, 0.79, 0.77 for CSS-3y, OS-3y and OS-5y respectively). ML is a promising technology in the field of UTUC. Our model achieve favorable results in terms of prediction of prognosis after RNU, especially in terms of CSS at 3 and 5 years, moreover is the first model of prognosis taking into account the differences in epidemiology existing between European and Asian patients. Further clinical validation and verification of its reliability for the case selection of adjuvant therapy are needed to assess its use in clinical practice linked to clinical decision making. ML is an advancing technology in the field of medicine and urology, which can also be applied to the definition of the prognosis of patients with UTUC undergoing RNU. Our study represents the first experience investigating this potential.

Indexed as

Machine LearningNephroureterectomyUreteral NeoplasmsUrologic NeoplasmsAgedFemaleHumansMaleNomogramsPredictive Learning ModelsPrognosisRetrospective StudiesMachine learningNephroureterectomyUpper tract urothelial cancer

Identifiers

PMID41565702
PMCPMC12827265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.